Search results

  1. Alcohol interventions in secondary and further education (NG135)

    This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

  2. Looked-after children and young people (NG205)

    This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.

  3. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

  4. Supporting adult carers (NG150)

    This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

  5. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

  6. End of life care for adults: service delivery (NG142)

    This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

  7. Behaviour change: digital and mobile health interventions (NG183)

    This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.

  8. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  9. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

  10. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

  11. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

  12. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

  13. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (DG43)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography

  14. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (DG39)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the

  15. High-sensitivity troponin tests for the early rule out of NSTEMI (DG40)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)

  16. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  17. Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat

  18. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

    Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in

  19. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic

  20. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

    Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions for people with early breast cancer. The tests are EndoPredict

  21. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

    Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are

  22. Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury (IPG687)

    Evidence-based recommendations on free-functioning gracilis transfer to restore upper limb function in brachial plexus injury in adults. This involves a piece o

  23. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG688)

    Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves

  24. Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (IPG689)

    Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a

  25. Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention (IPG673)

    Evidence-based recommendations on intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention in adults. This involves

  26. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney

  27. Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (IPG681)

    Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of

  28. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)

    Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures

  29. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (IPG657)

    Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults

  30. Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

    Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This

  31. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer (IPG659)

    Evidence-based recommendations on low-energy contact X ray brachytherapy (the Papillon technique) for locally advanced rectal cancer in adults